TY  - JOUR
AU  - Markićević, Milan
AU  - Džodić, Radan R.
AU  - Buta, Marko
AU  - Kanjer, Ksenija
AU  - Mandušić, Vesna
AU  - Nešković-Konstantinović, Zora
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/203
AB  - Background. A role of an estrogen-regulated, autocrine motogenic factor was assumed to be a major biological role of trefoil factor 1 (TFF1) in breast cancer. TFF1 is regarded as a predictive factor for positive response to endocrine therapy in breast cancer patients. The aim of our study was to examine TFF1 level distribution in breast carcinomas in order to distinguish estrogen-independent from estrogen-dependent TFF1 expression and to evaluate clinical usefulness of TFF1 status in early breast cancer during the first 3 years of follow-up. Methods. The study included 226 patients with primary operable invasive early breast carcinomas for whom an equal, a 3-year follow-up was conducted. TFF1 levels as well as estrogen receptor (ER) and progesterone receptor (PR) levels were measured in cytosolic extracts of tumor samples by immunoradiometric assay or by use of classical biochemical method, respectively. Non-parametric statistical tests were applied for data analyses. Results. Statistical analysis revealed that TFF1 levels were significantly higher in premenopausal patients (p=0.02), or in tumors with: lower histological grade (p LT 0.001), positive ER or PR status (p LT 0.001, in both cases). On the basis of TFF1 level distribution between ER-negative and ER-positive postmenopausal patients with tumors of different histological grade, 14 ng/mg was set as the cut-off value to distinguish estrogen-independent from estrogen-dependent TFF1 expression in breast cancer. Depending on menopausal and PR status, positive TFF1 status identified patients at opposite risk for relapse among ER-positive patients with grade II tumors. Among ER-and and PR-positive premenopausal patients with grade II tumors, TFF1 status alone identified patients at opposite risk for relapse. Conclusions. Determination of TFF1 status might identify patients at different risk for relapse and help in making decision on administering adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.
T2  - International Journal of Medical Sciences
T1  - Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up
VL  - 11
IS  - 7
SP  - 663
EP  - 673
DO  - 10.7150/ijms.8194
ER  - 

@article{
author = "Markićević, Milan and Džodić, Radan R. and Buta, Marko and Kanjer, Ksenija and Mandušić, Vesna and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica",
year = "2014",
abstract = "Background. A role of an estrogen-regulated, autocrine motogenic factor was assumed to be a major biological role of trefoil factor 1 (TFF1) in breast cancer. TFF1 is regarded as a predictive factor for positive response to endocrine therapy in breast cancer patients. The aim of our study was to examine TFF1 level distribution in breast carcinomas in order to distinguish estrogen-independent from estrogen-dependent TFF1 expression and to evaluate clinical usefulness of TFF1 status in early breast cancer during the first 3 years of follow-up. Methods. The study included 226 patients with primary operable invasive early breast carcinomas for whom an equal, a 3-year follow-up was conducted. TFF1 levels as well as estrogen receptor (ER) and progesterone receptor (PR) levels were measured in cytosolic extracts of tumor samples by immunoradiometric assay or by use of classical biochemical method, respectively. Non-parametric statistical tests were applied for data analyses. Results. Statistical analysis revealed that TFF1 levels were significantly higher in premenopausal patients (p=0.02), or in tumors with: lower histological grade (p LT 0.001), positive ER or PR status (p LT 0.001, in both cases). On the basis of TFF1 level distribution between ER-negative and ER-positive postmenopausal patients with tumors of different histological grade, 14 ng/mg was set as the cut-off value to distinguish estrogen-independent from estrogen-dependent TFF1 expression in breast cancer. Depending on menopausal and PR status, positive TFF1 status identified patients at opposite risk for relapse among ER-positive patients with grade II tumors. Among ER-and and PR-positive premenopausal patients with grade II tumors, TFF1 status alone identified patients at opposite risk for relapse. Conclusions. Determination of TFF1 status might identify patients at different risk for relapse and help in making decision on administering adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.",
journal = "International Journal of Medical Sciences",
title = "Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up",
volume = "11",
number = "7",
pages = "663-673",
doi = "10.7150/ijms.8194"
}

Markićević, M., Džodić, R. R., Buta, M., Kanjer, K., Mandušić, V., Nešković-Konstantinović, Z.,& Nikolić-Vukosavljević, D.. (2014). Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up. in International Journal of Medical Sciences, 11(7), 663-673.
https://doi.org/10.7150/ijms.8194

Markićević M, Džodić RR, Buta M, Kanjer K, Mandušić V, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up. in International Journal of Medical Sciences. 2014;11(7):663-673.
doi:10.7150/ijms.8194 .

Markićević, Milan, Džodić, Radan R., Buta, Marko, Kanjer, Ksenija, Mandušić, Vesna, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, "Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up" in International Journal of Medical Sciences, 11, no. 7 (2014):663-673,
https://doi.org/10.7150/ijms.8194 . .

TY  - JOUR
AU  - Markićević, Milan
AU  - Kanjer, Ksenija
AU  - Mandušić, Vesna
AU  - Buta, Marko
AU  - Nešković-Konstantinović, Zora
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5683
AB  - Aim: The aim of this study was to evaluate clinical usefulness of cathepsin D status in early breast cancer during the first 3 years of follow-up. Patients and methods: The study included 226 patients with histologically verified, primary operable invasive early breast carcinomas. Concentrations of estrogen receptor (ER) and progesterone receptor (PR) in breast tumor cytosols were measured by use of the classical biochemical method. The concentration of three cathepsin D forms (52-, 48- and 34-kDa proteins) was determined by a radioimmunoassay Results: On the basis of differences in cathepsin D levels either within an ER-/PR- phenotype or between this and either ER+/PR+ or ER+/PR- phenotypes, a concentration of 39 pmol/mg was determined as the cutoff value for distinguishing estrogen-regulated cathepsin D expression. Estrogen-regulated cathepsin D expression was recognized as a high-risk biomarker for low-risk (histological grade I) breast cancer patients and as a low-risk biomarker for high-risk patients (pN(+) pT2,3). Conclusion: Determination of cathepsin D status in breast cancer might identify patients at different risk for relapse and might facilitate the selection of more or less aggressive adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.
T2  - Biomarkers in Medicine
T1  - Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up
VL  - 7
IS  - 5
SP  - 747
EP  - 758
DO  - 10.2217/bmm.13.62
ER  - 

@article{
author = "Markićević, Milan and Kanjer, Ksenija and Mandušić, Vesna and Buta, Marko and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica",
year = "2013",
abstract = "Aim: The aim of this study was to evaluate clinical usefulness of cathepsin D status in early breast cancer during the first 3 years of follow-up. Patients and methods: The study included 226 patients with histologically verified, primary operable invasive early breast carcinomas. Concentrations of estrogen receptor (ER) and progesterone receptor (PR) in breast tumor cytosols were measured by use of the classical biochemical method. The concentration of three cathepsin D forms (52-, 48- and 34-kDa proteins) was determined by a radioimmunoassay Results: On the basis of differences in cathepsin D levels either within an ER-/PR- phenotype or between this and either ER+/PR+ or ER+/PR- phenotypes, a concentration of 39 pmol/mg was determined as the cutoff value for distinguishing estrogen-regulated cathepsin D expression. Estrogen-regulated cathepsin D expression was recognized as a high-risk biomarker for low-risk (histological grade I) breast cancer patients and as a low-risk biomarker for high-risk patients (pN(+) pT2,3). Conclusion: Determination of cathepsin D status in breast cancer might identify patients at different risk for relapse and might facilitate the selection of more or less aggressive adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.",
journal = "Biomarkers in Medicine",
title = "Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up",
volume = "7",
number = "5",
pages = "747-758",
doi = "10.2217/bmm.13.62"
}

Markićević, M., Kanjer, K., Mandušić, V., Buta, M., Nešković-Konstantinović, Z.,& Nikolić-Vukosavljević, D.. (2013). Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up. in Biomarkers in Medicine, 7(5), 747-758.
https://doi.org/10.2217/bmm.13.62

Markićević M, Kanjer K, Mandušić V, Buta M, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up. in Biomarkers in Medicine. 2013;7(5):747-758.
doi:10.2217/bmm.13.62 .

Markićević, Milan, Kanjer, Ksenija, Mandušić, Vesna, Buta, Marko, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, "Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up" in Biomarkers in Medicine, 7, no. 5 (2013):747-758,
https://doi.org/10.2217/bmm.13.62 . .

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Dimitrijević, Bogomir B.
AU  - Nikolić-Vukosavljević, Dragica
AU  - Nešković-Konstantinović, Zora
AU  - Kanjer, Ksenija
AU  - Hamann, Ute
PY  - 2012
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5002
AB  - Background: In breast cancer, little is known about the consequences of co-expression of ER alpha with the second estrogen receptor, ER beta, and its isoforms in light of their joint prognostic value. Previously reported correlations have been based mostly on independent ER alpha and ER beta expression levels in breast tumors. Purpose: To address whether the expression ratio of ER alpha and ER beta and its isoforms may be a more important parameter than their absolute levels, we analyzed relative mRNA expression ratios of ER beta 1 to ER beta 2 and ER alpha in 74 clinical samples of invasive breast cancer including 39 early-onset and 35 late-onset breast cancers. Expression levels were correlated with clinical and histopathological parameters and disease-free interval. Results: A specific correlation of ER beta 1 expression levels with tumor size was detected in early-onset breast cancer patients and of ER beta 2 levels with tumor size in late-onset patients. Expression of both ER beta isoforms inversely correlated with expression of the two estrogen regulated genes, progesterone receptor and pS2 in both groups. Higher levels of ER beta 2 than ER beta 1 isoform were associated with a better outcome in late-onset patients. Conclusions: Our results suggest that different isoforms of ER beta may be involved in suppression of tumor growth in young and elder patients and may have different prognostic values. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
T2  - Cancer Letters
T1  - Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer
VL  - 321
IS  - 1
SP  - 73
EP  - 79
DO  - 10.1016/j.canlet.2012.02.022
ER  - 

@article{
author = "Mandušić, Vesna and Dimitrijević, Bogomir B. and Nikolić-Vukosavljević, Dragica and Nešković-Konstantinović, Zora and Kanjer, Ksenija and Hamann, Ute",
year = "2012",
abstract = "Background: In breast cancer, little is known about the consequences of co-expression of ER alpha with the second estrogen receptor, ER beta, and its isoforms in light of their joint prognostic value. Previously reported correlations have been based mostly on independent ER alpha and ER beta expression levels in breast tumors. Purpose: To address whether the expression ratio of ER alpha and ER beta and its isoforms may be a more important parameter than their absolute levels, we analyzed relative mRNA expression ratios of ER beta 1 to ER beta 2 and ER alpha in 74 clinical samples of invasive breast cancer including 39 early-onset and 35 late-onset breast cancers. Expression levels were correlated with clinical and histopathological parameters and disease-free interval. Results: A specific correlation of ER beta 1 expression levels with tumor size was detected in early-onset breast cancer patients and of ER beta 2 levels with tumor size in late-onset patients. Expression of both ER beta isoforms inversely correlated with expression of the two estrogen regulated genes, progesterone receptor and pS2 in both groups. Higher levels of ER beta 2 than ER beta 1 isoform were associated with a better outcome in late-onset patients. Conclusions: Our results suggest that different isoforms of ER beta may be involved in suppression of tumor growth in young and elder patients and may have different prognostic values. (C) 2012 Elsevier Ireland Ltd. All rights reserved.",
journal = "Cancer Letters",
title = "Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer",
volume = "321",
number = "1",
pages = "73-79",
doi = "10.1016/j.canlet.2012.02.022"
}

Mandušić, V., Dimitrijević, B. B., Nikolić-Vukosavljević, D., Nešković-Konstantinović, Z., Kanjer, K.,& Hamann, U.. (2012). Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer. in Cancer Letters, 321(1), 73-79.
https://doi.org/10.1016/j.canlet.2012.02.022

Mandušić V, Dimitrijević BB, Nikolić-Vukosavljević D, Nešković-Konstantinović Z, Kanjer K, Hamann U. Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer. in Cancer Letters. 2012;321(1):73-79.
doi:10.1016/j.canlet.2012.02.022 .

Mandušić, Vesna, Dimitrijević, Bogomir B., Nikolić-Vukosavljević, Dragica, Nešković-Konstantinović, Zora, Kanjer, Ksenija, Hamann, Ute, "Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer" in Cancer Letters, 321, no. 1 (2012):73-79,
https://doi.org/10.1016/j.canlet.2012.02.022 . .

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Popov-Celeketic, Dusan
AU  - Nešković-Konstantinović, Zora
AU  - Kanjer, Ksenija
AU  - Božović, Ana M.
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2010
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4046
AB  - It is well known that breast tumors which are estrogen positive ER(+) are more likely to respond to hormone therapy. However, a certain percentage of ER(+)/PR(+) tumors do not respond to this therapy. Identification of the second estrogen receptor, named estrogen receptor beta (ER), as well as the existence of numerous isoforms/splice variants of both ER alpha and ER beta, suggests that a complex regulation of estrogen action exists. In this study, we analyzed the expression ratio of ER beta 1 isoform and ER beta Delta 5 splice variant mRNAs, and its correlation with ER/PR status by quantitative RT-PCR and clinical and histopathological parameters. We found that the relative proportion of ER beta Delta 5 in the total ER beta 1 transcript pool inversely correlates with the PR level (rho = -0,359, p LT 0,003, Spearman). It may be that the ER beta Delta 5 variant modulates the ERa activity of downstream targets. In addition, we suggest that the determination of the expression profiles of ER alpha and ER beta isoforms and splice variants in the defined groups of patients are necessary for elucidating their involvement in endocrine resistance.
T2  - Archives of Biological Sciences
T1  - Levels of Estrogen Receptor B Splice Variant (Erb Delta 5) Mrna Correlates with Progesterone Receptor in Breast Carcinomas
VL  - 62
IS  - 2
SP  - 257
EP  - 262
DO  - 10.2298/ABS1002257M
ER  - 

@article{
author = "Mandušić, Vesna and Popov-Celeketic, Dusan and Nešković-Konstantinović, Zora and Kanjer, Ksenija and Božović, Ana M. and Nikolić-Vukosavljević, Dragica",
year = "2010",
abstract = "It is well known that breast tumors which are estrogen positive ER(+) are more likely to respond to hormone therapy. However, a certain percentage of ER(+)/PR(+) tumors do not respond to this therapy. Identification of the second estrogen receptor, named estrogen receptor beta (ER), as well as the existence of numerous isoforms/splice variants of both ER alpha and ER beta, suggests that a complex regulation of estrogen action exists. In this study, we analyzed the expression ratio of ER beta 1 isoform and ER beta Delta 5 splice variant mRNAs, and its correlation with ER/PR status by quantitative RT-PCR and clinical and histopathological parameters. We found that the relative proportion of ER beta Delta 5 in the total ER beta 1 transcript pool inversely correlates with the PR level (rho = -0,359, p LT 0,003, Spearman). It may be that the ER beta Delta 5 variant modulates the ERa activity of downstream targets. In addition, we suggest that the determination of the expression profiles of ER alpha and ER beta isoforms and splice variants in the defined groups of patients are necessary for elucidating their involvement in endocrine resistance.",
journal = "Archives of Biological Sciences",
title = "Levels of Estrogen Receptor B Splice Variant (Erb Delta 5) Mrna Correlates with Progesterone Receptor in Breast Carcinomas",
volume = "62",
number = "2",
pages = "257-262",
doi = "10.2298/ABS1002257M"
}

Mandušić, V., Popov-Celeketic, D., Nešković-Konstantinović, Z., Kanjer, K., Božović, A. M.,& Nikolić-Vukosavljević, D.. (2010). Levels of Estrogen Receptor B Splice Variant (Erb Delta 5) Mrna Correlates with Progesterone Receptor in Breast Carcinomas. in Archives of Biological Sciences, 62(2), 257-262.
https://doi.org/10.2298/ABS1002257M

Mandušić V, Popov-Celeketic D, Nešković-Konstantinović Z, Kanjer K, Božović AM, Nikolić-Vukosavljević D. Levels of Estrogen Receptor B Splice Variant (Erb Delta 5) Mrna Correlates with Progesterone Receptor in Breast Carcinomas. in Archives of Biological Sciences. 2010;62(2):257-262.
doi:10.2298/ABS1002257M .

Mandušić, Vesna, Popov-Celeketic, Dusan, Nešković-Konstantinović, Zora, Kanjer, Ksenija, Božović, Ana M., Nikolić-Vukosavljević, Dragica, "Levels of Estrogen Receptor B Splice Variant (Erb Delta 5) Mrna Correlates with Progesterone Receptor in Breast Carcinomas" in Archives of Biological Sciences, 62, no. 2 (2010):257-262,
https://doi.org/10.2298/ABS1002257M . .

TY  - JOUR
AU  - Adžić, Miroslav
AU  - Nićiforović, Ana
AU  - Zarić, Božidarka
AU  - Nešković-Konstantinović, Zora
AU  - Spasić, Snežana D.
AU  - Jones, David R.
AU  - Radojčić, Marija
PY  - 2008
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3490
AB  - To compare the effects of ionising radiation on leukocytes from breast cancer patients and healthy subjects ex vivo, the level of NF-kappa B and the antioxidant enzymes manganese-containing superoxide dismutase (Mn-SOD), copper/zinc-containing superoxide dismutase (CuZn-SOD) and catalase (CAT) in combination with flow cytometric analysis of CD4(+) lymphocytes was performed. The level of Mn-SOD protein was significantly increased in the breast cancer study group both before (P LT 0.001) and after (P LT 0.001) irradiation when compared with healthy subjects. Measurements in parallel indicated that the level of CAT protein was significantly higher in the breast cancer study group after irradiation (2 Gy [P LT 0.001] and 9 Gy [P LT 0.05]) when compared with healthy subjects. Although the initial number of lymphocytes in the blood of breast cancer patients was not different from healthy subjects, the percentage of apoptotic CD4(+) cells was significantly (P LT 0.001) lower both before and after irradiation indicating that cell culture conditions induced radioresistance of CD4(+) cells in the blood of breast cancer patients. The data presented in this current study indicate that brief ex vivo culture of peripheral blood leukocytes potentiates oxidative stress imposed by a breast cancer tumour.
T2  - Redox Report
T1  - Cell culture conditions potentiate differences in the response to ionising radiation of peripheral blood leukocytes isolated from breast cancer patients and healthy subjects
VL  - 13
IS  - 1
SP  - 17
EP  - 22
DO  - 10.1179/135100008X259088
ER  - 

@article{
author = "Adžić, Miroslav and Nićiforović, Ana and Zarić, Božidarka and Nešković-Konstantinović, Zora and Spasić, Snežana D. and Jones, David R. and Radojčić, Marija",
year = "2008",
abstract = "To compare the effects of ionising radiation on leukocytes from breast cancer patients and healthy subjects ex vivo, the level of NF-kappa B and the antioxidant enzymes manganese-containing superoxide dismutase (Mn-SOD), copper/zinc-containing superoxide dismutase (CuZn-SOD) and catalase (CAT) in combination with flow cytometric analysis of CD4(+) lymphocytes was performed. The level of Mn-SOD protein was significantly increased in the breast cancer study group both before (P LT 0.001) and after (P LT 0.001) irradiation when compared with healthy subjects. Measurements in parallel indicated that the level of CAT protein was significantly higher in the breast cancer study group after irradiation (2 Gy [P LT 0.001] and 9 Gy [P LT 0.05]) when compared with healthy subjects. Although the initial number of lymphocytes in the blood of breast cancer patients was not different from healthy subjects, the percentage of apoptotic CD4(+) cells was significantly (P LT 0.001) lower both before and after irradiation indicating that cell culture conditions induced radioresistance of CD4(+) cells in the blood of breast cancer patients. The data presented in this current study indicate that brief ex vivo culture of peripheral blood leukocytes potentiates oxidative stress imposed by a breast cancer tumour.",
journal = "Redox Report",
title = "Cell culture conditions potentiate differences in the response to ionising radiation of peripheral blood leukocytes isolated from breast cancer patients and healthy subjects",
volume = "13",
number = "1",
pages = "17-22",
doi = "10.1179/135100008X259088"
}

Adžić, M., Nićiforović, A., Zarić, B., Nešković-Konstantinović, Z., Spasić, S. D., Jones, D. R.,& Radojčić, M.. (2008). Cell culture conditions potentiate differences in the response to ionising radiation of peripheral blood leukocytes isolated from breast cancer patients and healthy subjects. in Redox Report, 13(1), 17-22.
https://doi.org/10.1179/135100008X259088

Adžić M, Nićiforović A, Zarić B, Nešković-Konstantinović Z, Spasić SD, Jones DR, Radojčić M. Cell culture conditions potentiate differences in the response to ionising radiation of peripheral blood leukocytes isolated from breast cancer patients and healthy subjects. in Redox Report. 2008;13(1):17-22.
doi:10.1179/135100008X259088 .

Adžić, Miroslav, Nićiforović, Ana, Zarić, Božidarka, Nešković-Konstantinović, Zora, Spasić, Snežana D., Jones, David R., Radojčić, Marija, "Cell culture conditions potentiate differences in the response to ionising radiation of peripheral blood leukocytes isolated from breast cancer patients and healthy subjects" in Redox Report, 13, no. 1 (2008):17-22,
https://doi.org/10.1179/135100008X259088 . .

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Nikolić-Vukosavljević, Dragica
AU  - Tanić, Nikola
AU  - Kanjer, Ksenija
AU  - Nešković-Konstantinović, Zora
AU  - Celeketic, Dusica
AU  - Dimitrijević, Bogomir B.
PY  - 2007
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2576
AB  - Purpose In addition to Estrogen Receptor alpha (ER alpha) and Progesterone Receptor (PR), the Second Estrogen Receptor (ER beta) appears to play an important role not only in estrogen signaling, but also in the pathogenesis of cancer in estrogen dependent tissues. The existence of various isoforms and splice variants of both ERs additionally complicates elucidation of their physiological role and involvement in the process of carcinogenesis. Methods In this study, the expression of ER beta 1 mRNA (wild type of beta receptor) and splice variant ER beta Delta 5 mRNA (which codes for truncated protein) was measured by the quantitative RT-PCR (q RT-PCR) in the 60 samples of Breast Cancer (BC) and correlated with ER alpha and PR protein levels and with clinical and histopathological parameters. Results We found the inverse correlation of ER beta Delta 5 mRNA expression with the levels of PR and ER alpha proteins in the group of postmenopausal patients; we also report the lower expression of ER beta 1 and ER beta Delta 5 mRNA in the larger tumors ( GT 20 mm, T2, and T3) than in smaller ones ( LT = 20 mm, T1). The decrease of ER beta Delta 5 mRNA expression in larger tumors is found to arise from ER-positive breast carcinomas. In addition, the portion of tumors with concomitant high expression of both transcripts matches up the known percentage of tumors resistant to endocrine therapy in patients with different ER/PR status. Conclusions As far as we know, this is the first study in which ER beta Delta 5 mRNA splice variant was quantified by realtime RT-PCR in the clinical samples of breast cancer tissue. Until now, the focus of clinical reports was the level of ER beta 1, ER beta 2, and ER beta 5 isoforms. The higher expression of ER beta Delta 5 mRNA is associated with the indicators of low biological aggressiveness of tumor (low tumor size within ER-positive status in our study) suggesting that the uncontrolled local tumor growth may occur as the expression of ER beta Delta 5 mRNA decreases in estrogen-dependent breast cancer.
T2  - Journal of Cancer Research and Clinical Oncology
T1  - Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer
VL  - 133
IS  - 8
SP  - 571
EP  - 579
DO  - 10.1007/s00432-007-0209-x
ER  - 

@article{
author = "Mandušić, Vesna and Nikolić-Vukosavljević, Dragica and Tanić, Nikola and Kanjer, Ksenija and Nešković-Konstantinović, Zora and Celeketic, Dusica and Dimitrijević, Bogomir B.",
year = "2007",
abstract = "Purpose In addition to Estrogen Receptor alpha (ER alpha) and Progesterone Receptor (PR), the Second Estrogen Receptor (ER beta) appears to play an important role not only in estrogen signaling, but also in the pathogenesis of cancer in estrogen dependent tissues. The existence of various isoforms and splice variants of both ERs additionally complicates elucidation of their physiological role and involvement in the process of carcinogenesis. Methods In this study, the expression of ER beta 1 mRNA (wild type of beta receptor) and splice variant ER beta Delta 5 mRNA (which codes for truncated protein) was measured by the quantitative RT-PCR (q RT-PCR) in the 60 samples of Breast Cancer (BC) and correlated with ER alpha and PR protein levels and with clinical and histopathological parameters. Results We found the inverse correlation of ER beta Delta 5 mRNA expression with the levels of PR and ER alpha proteins in the group of postmenopausal patients; we also report the lower expression of ER beta 1 and ER beta Delta 5 mRNA in the larger tumors ( GT 20 mm, T2, and T3) than in smaller ones ( LT = 20 mm, T1). The decrease of ER beta Delta 5 mRNA expression in larger tumors is found to arise from ER-positive breast carcinomas. In addition, the portion of tumors with concomitant high expression of both transcripts matches up the known percentage of tumors resistant to endocrine therapy in patients with different ER/PR status. Conclusions As far as we know, this is the first study in which ER beta Delta 5 mRNA splice variant was quantified by realtime RT-PCR in the clinical samples of breast cancer tissue. Until now, the focus of clinical reports was the level of ER beta 1, ER beta 2, and ER beta 5 isoforms. The higher expression of ER beta Delta 5 mRNA is associated with the indicators of low biological aggressiveness of tumor (low tumor size within ER-positive status in our study) suggesting that the uncontrolled local tumor growth may occur as the expression of ER beta Delta 5 mRNA decreases in estrogen-dependent breast cancer.",
journal = "Journal of Cancer Research and Clinical Oncology",
title = "Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer",
volume = "133",
number = "8",
pages = "571-579",
doi = "10.1007/s00432-007-0209-x"
}

Mandušić, V., Nikolić-Vukosavljević, D., Tanić, N., Kanjer, K., Nešković-Konstantinović, Z., Celeketic, D.,& Dimitrijević, B. B.. (2007). Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer. in Journal of Cancer Research and Clinical Oncology, 133(8), 571-579.
https://doi.org/10.1007/s00432-007-0209-x

Mandušić V, Nikolić-Vukosavljević D, Tanić N, Kanjer K, Nešković-Konstantinović Z, Celeketic D, Dimitrijević BB. Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer. in Journal of Cancer Research and Clinical Oncology. 2007;133(8):571-579.
doi:10.1007/s00432-007-0209-x .

Mandušić, Vesna, Nikolić-Vukosavljević, Dragica, Tanić, Nikola, Kanjer, Ksenija, Nešković-Konstantinović, Zora, Celeketic, Dusica, Dimitrijević, Bogomir B., "Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer" in Journal of Cancer Research and Clinical Oncology, 133, no. 8 (2007):571-579,
https://doi.org/10.1007/s00432-007-0209-x . .

TY  - CONF
AU  - Nikolić-Vukosavljević, Dragica
AU  - Mandušić, Vesna
AU  - Nešković-Konstantinović, Zora
AU  - Dimitrijević, Bogomir B.
PY  - 2007
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3479
C3  - Breast
T1  - Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance
VL  - 16
SP  - S13
EP  - S14
DO  - 10.1016/S0960-9776(07)70069-3
ER  - 

@conference{
author = "Nikolić-Vukosavljević, Dragica and Mandušić, Vesna and Nešković-Konstantinović, Zora and Dimitrijević, Bogomir B.",
year = "2007",
journal = "Breast",
title = "Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance",
volume = "16",
pages = "S13-S14",
doi = "10.1016/S0960-9776(07)70069-3"
}

Nikolić-Vukosavljević, D., Mandušić, V., Nešković-Konstantinović, Z.,& Dimitrijević, B. B.. (2007). Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance. in Breast, 16, S13-S14.
https://doi.org/10.1016/S0960-9776(07)70069-3

Nikolić-Vukosavljević D, Mandušić V, Nešković-Konstantinović Z, Dimitrijević BB. Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance. in Breast. 2007;16:S13-S14.
doi:10.1016/S0960-9776(07)70069-3 .

Nikolić-Vukosavljević, Dragica, Mandušić, Vesna, Nešković-Konstantinović, Zora, Dimitrijević, Bogomir B., "Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance" in Breast, 16 (2007):S13-S14,
https://doi.org/10.1016/S0960-9776(07)70069-3 . .

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Demajo, Miroslav
AU  - Krtolica-Žikić, Koviljka
AU  - Krajnović, Milena M.
AU  - Dimitrijević, Bogomir B.
AU  - Konstantinovic, M.
AU  - Baltić, Vladimir
AU  - Prtenjak, Gordana
AU  - Stojiljković, Bratislav
AU  - Breberina, Milan
AU  - Nešković-Konstantinović, Zora
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2006
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3079
AB  - Background: The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients. Methods: Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the T beta RII receptor-based Quantikine TGF-beta(1) ELISA kit. Results: The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n = 37; p GT 0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p LT 0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) ( GT 3.00 ng/ml; n=10), was 10%. This was significantly decreased (p LT 0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGF beta(1) values close to HD ( LT 3.00 ng/ml, n=19). Conclusion: We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis. (c) 2006 Elsevier B.V. All rights reserved.
T2  - Clinica Chimica Acta
T1  - Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients
VL  - 371
IS  - 1-2
SP  - 191
EP  - 193
DO  - 10.1016/j.cca.2006.02.027
ER  - 

@article{
author = "Ivanović, Vesna and Demajo, Miroslav and Krtolica-Žikić, Koviljka and Krajnović, Milena M. and Dimitrijević, Bogomir B. and Konstantinovic, M. and Baltić, Vladimir and Prtenjak, Gordana and Stojiljković, Bratislav and Breberina, Milan and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica",
year = "2006",
abstract = "Background: The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients. Methods: Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the T beta RII receptor-based Quantikine TGF-beta(1) ELISA kit. Results: The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n = 37; p GT 0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p LT 0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) ( GT 3.00 ng/ml; n=10), was 10%. This was significantly decreased (p LT 0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGF beta(1) values close to HD ( LT 3.00 ng/ml, n=19). Conclusion: We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis. (c) 2006 Elsevier B.V. All rights reserved.",
journal = "Clinica Chimica Acta",
title = "Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients",
volume = "371",
number = "1-2",
pages = "191-193",
doi = "10.1016/j.cca.2006.02.027"
}

Ivanović, V., Demajo, M., Krtolica-Žikić, K., Krajnović, M. M., Dimitrijević, B. B., Konstantinovic, M., Baltić, V., Prtenjak, G., Stojiljković, B., Breberina, M., Nešković-Konstantinović, Z.,& Nikolić-Vukosavljević, D.. (2006). Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients. in Clinica Chimica Acta, 371(1-2), 191-193.
https://doi.org/10.1016/j.cca.2006.02.027

Ivanović V, Demajo M, Krtolica-Žikić K, Krajnović MM, Dimitrijević BB, Konstantinovic M, Baltić V, Prtenjak G, Stojiljković B, Breberina M, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients. in Clinica Chimica Acta. 2006;371(1-2):191-193.
doi:10.1016/j.cca.2006.02.027 .

Ivanović, Vesna, Demajo, Miroslav, Krtolica-Žikić, Koviljka, Krajnović, Milena M., Dimitrijević, Bogomir B., Konstantinovic, M., Baltić, Vladimir, Prtenjak, Gordana, Stojiljković, Bratislav, Breberina, Milan, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, "Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients" in Clinica Chimica Acta, 371, no. 1-2 (2006):191-193,
https://doi.org/10.1016/j.cca.2006.02.027 . .

TY  - JOUR
AU  - Adžić, Miroslav
AU  - Nićiforović, Ana
AU  - Vučić, Vesna
AU  - Nešković-Konstantinović, Zora
AU  - Spasić, Snežana D.
AU  - Jones, David R.
AU  - Radoičić, Marija B.
AU  - Spasić, Mihajlo
PY  - 2006
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3008
AB  - There is a well-established role for reactive oxygen and nitrogen species, chronic inflammation and immune response in the pathogenesis of breast cancer. Complex interactions between breast cancer cells and surrounding blood vessels are prerequisites for cancer growth and invasion. Reports in the literature concerning the systemic response to, and the effect of, common breast cancer therapy on NF-kappa B and antioxidative defence enzyme expression and activity under clinical conditions are scarce. We determined these parameters in whole blood cell lysate from 16 women with breast cancer before and after combined (cyclophosphamide, doxorubicin, 5-fluorouracil; CAF) therapy and compared the results with 16 healthy women. Significantly higher levels of NF-kappa B and Mn-SOD (both their protein level and their activity) were found in breast cancer patients before and after CAF therapy, in comparison with healthy women. In parallel measurements, no change in the level or activity of catalase (CAT) was detected. According to our findings, it appears that breast cancer creates conditions that increase the level of hydrogen peroxide in the circulating cells and that the applied CAF therapy fails to compensate, therefore creating systemic conditions that favour survival and invasion of breast cancer cells.
T2  - Redox Report
T1  - Systemic NF-κB activation in blood cells of breast cancer patients
VL  - 11
IS  - 1
SP  - 38
EP  - 44
DO  - 10.1179/135100006X101002
ER  - 

@article{
author = "Adžić, Miroslav and Nićiforović, Ana and Vučić, Vesna and Nešković-Konstantinović, Zora and Spasić, Snežana D. and Jones, David R. and Radoičić, Marija B. and Spasić, Mihajlo",
year = "2006",
abstract = "There is a well-established role for reactive oxygen and nitrogen species, chronic inflammation and immune response in the pathogenesis of breast cancer. Complex interactions between breast cancer cells and surrounding blood vessels are prerequisites for cancer growth and invasion. Reports in the literature concerning the systemic response to, and the effect of, common breast cancer therapy on NF-kappa B and antioxidative defence enzyme expression and activity under clinical conditions are scarce. We determined these parameters in whole blood cell lysate from 16 women with breast cancer before and after combined (cyclophosphamide, doxorubicin, 5-fluorouracil; CAF) therapy and compared the results with 16 healthy women. Significantly higher levels of NF-kappa B and Mn-SOD (both their protein level and their activity) were found in breast cancer patients before and after CAF therapy, in comparison with healthy women. In parallel measurements, no change in the level or activity of catalase (CAT) was detected. According to our findings, it appears that breast cancer creates conditions that increase the level of hydrogen peroxide in the circulating cells and that the applied CAF therapy fails to compensate, therefore creating systemic conditions that favour survival and invasion of breast cancer cells.",
journal = "Redox Report",
title = "Systemic NF-κB activation in blood cells of breast cancer patients",
volume = "11",
number = "1",
pages = "38-44",
doi = "10.1179/135100006X101002"
}

Adžić, M., Nićiforović, A., Vučić, V., Nešković-Konstantinović, Z., Spasić, S. D., Jones, D. R., Radoičić, M. B.,& Spasić, M.. (2006). Systemic NF-κB activation in blood cells of breast cancer patients. in Redox Report, 11(1), 38-44.
https://doi.org/10.1179/135100006X101002

Adžić M, Nićiforović A, Vučić V, Nešković-Konstantinović Z, Spasić SD, Jones DR, Radoičić MB, Spasić M. Systemic NF-κB activation in blood cells of breast cancer patients. in Redox Report. 2006;11(1):38-44.
doi:10.1179/135100006X101002 .

Adžić, Miroslav, Nićiforović, Ana, Vučić, Vesna, Nešković-Konstantinović, Zora, Spasić, Snežana D., Jones, David R., Radoičić, Marija B., Spasić, Mihajlo, "Systemic NF-κB activation in blood cells of breast cancer patients" in Redox Report, 11, no. 1 (2006):38-44,
https://doi.org/10.1179/135100006X101002 . .

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Demajo, Miroslav
AU  - Todorović-Raković, N
AU  - Nikolić-Vukosavljević, Dragica
AU  - Nešković-Konstantinović, Zora
AU  - Krtolica-Žikić, Koviljka
AU  - Veljković, Veljko
AU  - Prljić, Jelena
AU  - Dimitrijević, Bogomir B.
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2769
AB  - Although overexpression of TGF-beta(1) protein has been demonstrated in advanced breast cancer(BC) patients, as well as in other solid tumours, the molecular mechanism of this process remains obscure. This paper proposes that a genetic/epigenetic alteration might occur in the TGF-beta(1) gene, within the region coding for the recognition site with TGF(beta) receptor type II, leading to a disruption of the ligand-receptor interaction and triggering the TGF-beta(1) cascade-related BC progression. To establish the operational framework for this hypothesis, in the present study, this recognition site was identified by the Informational Spectrum Method (ISM) to comprise two TGF-beta(1) peptides (positions 47-66 as and 83-112 aa) and one receptor peptide at positions 112-151 as of the extracellular domain of the receptor (TbetaRII(M)). The TbetaRII(M) locus was further evaluated by ISM-derived deletion analysis of the TbetaRII sequences. To provide experimental support for the proposed model, a pilot study of plasma TGF-beta(1) analysis was performed in advanced BC patients (n = 8). Two commercial ELISA assays, one with specific alphaTGF-beta(1) MAb (MAb) and other with TbetaRII(M) as the immobilized phase, revealed pronounced differences in the pattern of plasma TGF-beta(1) elevation. In MAb-profile, the TGF-beta(1) increase was detected in 7 of 8 patients, whereas analogous TbetaRII(M)-profile revealed the elevation in 3 of 8 patients, taking a 50% of maximal elevation as the cut-off value. These findings are consistent with the proposed aberration of TGF-beta(1) ligand within the TbetaRII recognition site. Summarizing, this model system is a good starting point for further genetic studies, particularly on genetic/epigenetic alterations of sequences involved in TGF-beta(1) and TbetaRII(M) interaction, with putative prognostic value for breast cancer. (C) 2004 Elsevier Ltd. All rights reserved.
T2  - Medical Hypotheses
T1  - Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer
VL  - 62
IS  - 5
SP  - 727
EP  - 732
DO  - 10.1016/j.mehy.2003.11.027
ER  - 

@article{
author = "Ivanović, Vesna and Demajo, Miroslav and Todorović-Raković, N and Nikolić-Vukosavljević, Dragica and Nešković-Konstantinović, Zora and Krtolica-Žikić, Koviljka and Veljković, Veljko and Prljić, Jelena and Dimitrijević, Bogomir B.",
year = "2004",
abstract = "Although overexpression of TGF-beta(1) protein has been demonstrated in advanced breast cancer(BC) patients, as well as in other solid tumours, the molecular mechanism of this process remains obscure. This paper proposes that a genetic/epigenetic alteration might occur in the TGF-beta(1) gene, within the region coding for the recognition site with TGF(beta) receptor type II, leading to a disruption of the ligand-receptor interaction and triggering the TGF-beta(1) cascade-related BC progression. To establish the operational framework for this hypothesis, in the present study, this recognition site was identified by the Informational Spectrum Method (ISM) to comprise two TGF-beta(1) peptides (positions 47-66 as and 83-112 aa) and one receptor peptide at positions 112-151 as of the extracellular domain of the receptor (TbetaRII(M)). The TbetaRII(M) locus was further evaluated by ISM-derived deletion analysis of the TbetaRII sequences. To provide experimental support for the proposed model, a pilot study of plasma TGF-beta(1) analysis was performed in advanced BC patients (n = 8). Two commercial ELISA assays, one with specific alphaTGF-beta(1) MAb (MAb) and other with TbetaRII(M) as the immobilized phase, revealed pronounced differences in the pattern of plasma TGF-beta(1) elevation. In MAb-profile, the TGF-beta(1) increase was detected in 7 of 8 patients, whereas analogous TbetaRII(M)-profile revealed the elevation in 3 of 8 patients, taking a 50% of maximal elevation as the cut-off value. These findings are consistent with the proposed aberration of TGF-beta(1) ligand within the TbetaRII recognition site. Summarizing, this model system is a good starting point for further genetic studies, particularly on genetic/epigenetic alterations of sequences involved in TGF-beta(1) and TbetaRII(M) interaction, with putative prognostic value for breast cancer. (C) 2004 Elsevier Ltd. All rights reserved.",
journal = "Medical Hypotheses",
title = "Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer",
volume = "62",
number = "5",
pages = "727-732",
doi = "10.1016/j.mehy.2003.11.027"
}

Ivanović, V., Demajo, M., Todorović-Raković, N., Nikolić-Vukosavljević, D., Nešković-Konstantinović, Z., Krtolica-Žikić, K., Veljković, V., Prljić, J.,& Dimitrijević, B. B.. (2004). Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer. in Medical Hypotheses, 62(5), 727-732.
https://doi.org/10.1016/j.mehy.2003.11.027

Ivanović V, Demajo M, Todorović-Raković N, Nikolić-Vukosavljević D, Nešković-Konstantinović Z, Krtolica-Žikić K, Veljković V, Prljić J, Dimitrijević BB. Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer. in Medical Hypotheses. 2004;62(5):727-732.
doi:10.1016/j.mehy.2003.11.027 .

Ivanović, Vesna, Demajo, Miroslav, Todorović-Raković, N, Nikolić-Vukosavljević, Dragica, Nešković-Konstantinović, Zora, Krtolica-Žikić, Koviljka, Veljković, Veljko, Prljić, Jelena, Dimitrijević, Bogomir B., "Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer" in Medical Hypotheses, 62, no. 5 (2004):727-732,
https://doi.org/10.1016/j.mehy.2003.11.027 . .

TY  - JOUR
AU  - Adžić, Miroslav
AU  - Nićiforović, Ana
AU  - Nešković-Konstantinović, Zora
AU  - Radojčić, Marija B.
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10582
AB  - Purpose: Radiation treatment of breast cancer (BC) often results in post-therapy complications. The undesired sequelae could be avoided by the diagnostic screening of biomarkers for prediction of ionizing radiation (IR)-linked injury of healthy tissues. Patients and methods: The expression of antioxidative defence enzymes CuZn- and Mn-superoxide dismutase (CuZnSOD, MnSOD) and tumor suppressor protein p53 was measured in blood cells of 19 women with BC (age groups 30-45 and 46-60 years) and of the respective controls. The proteins were detected by specific immunostaining and quantified by laser-scanning densitometry. Results: Constitutive expression of CuZnSOD was significantly elevated in the group of BC patients (up to 254 arbitrary units, AU/mL) relative to the control group (105-130 AU/mL). The constitutive expression of MnSOD was elevated (up to 94 AU/mL) in the group of BC patients relative to the controls (53-56 AU/mL). p53 was also constitutively more expressed in BC patients (35-42 AU/mL) than in controls (32-33 AU/mL). Both MnSOD and p53 were inducible by 60Co gamma-ray IR (up to 170 AU/mL and 51 AU/mL, respectively) in the BC patient group. The levels of IR-induced p53 correlated inversely with MnSOD levels. Conclusion: The constitutive expression of all 3 proteins could be a useful biomarker for the presence of BC, but only MnSOD overexpression may be the predictive biomarker for selection of BC patients that would be less susceptible to IR-linked complications. © 2004 Zerbinis Medical Publications.
T2  - Journal of Balkan Union of Oncology.
T1  - Superoxide dismutases and p53 protein levels in blood cells of breast cancer patients
VL  - 9
IS  - 3
SP  - 283
EP  - 287
UR  - https://hdl.handle.net/21.15107/rcub_vinar_10582
ER  - 

@article{
author = "Adžić, Miroslav and Nićiforović, Ana and Nešković-Konstantinović, Zora and Radojčić, Marija B.",
year = "2004",
abstract = "Purpose: Radiation treatment of breast cancer (BC) often results in post-therapy complications. The undesired sequelae could be avoided by the diagnostic screening of biomarkers for prediction of ionizing radiation (IR)-linked injury of healthy tissues. Patients and methods: The expression of antioxidative defence enzymes CuZn- and Mn-superoxide dismutase (CuZnSOD, MnSOD) and tumor suppressor protein p53 was measured in blood cells of 19 women with BC (age groups 30-45 and 46-60 years) and of the respective controls. The proteins were detected by specific immunostaining and quantified by laser-scanning densitometry. Results: Constitutive expression of CuZnSOD was significantly elevated in the group of BC patients (up to 254 arbitrary units, AU/mL) relative to the control group (105-130 AU/mL). The constitutive expression of MnSOD was elevated (up to 94 AU/mL) in the group of BC patients relative to the controls (53-56 AU/mL). p53 was also constitutively more expressed in BC patients (35-42 AU/mL) than in controls (32-33 AU/mL). Both MnSOD and p53 were inducible by 60Co gamma-ray IR (up to 170 AU/mL and 51 AU/mL, respectively) in the BC patient group. The levels of IR-induced p53 correlated inversely with MnSOD levels. Conclusion: The constitutive expression of all 3 proteins could be a useful biomarker for the presence of BC, but only MnSOD overexpression may be the predictive biomarker for selection of BC patients that would be less susceptible to IR-linked complications. © 2004 Zerbinis Medical Publications.",
journal = "Journal of Balkan Union of Oncology.",
title = "Superoxide dismutases and p53 protein levels in blood cells of breast cancer patients",
volume = "9",
number = "3",
pages = "283-287",
url = "https://hdl.handle.net/21.15107/rcub_vinar_10582"
}

Adžić, M., Nićiforović, A., Nešković-Konstantinović, Z.,& Radojčić, M. B.. (2004). Superoxide dismutases and p53 protein levels in blood cells of breast cancer patients. in Journal of Balkan Union of Oncology., 9(3), 283-287.
https://hdl.handle.net/21.15107/rcub_vinar_10582

Adžić M, Nićiforović A, Nešković-Konstantinović Z, Radojčić MB. Superoxide dismutases and p53 protein levels in blood cells of breast cancer patients. in Journal of Balkan Union of Oncology.. 2004;9(3):283-287.
https://hdl.handle.net/21.15107/rcub_vinar_10582 .

Adžić, Miroslav, Nićiforović, Ana, Nešković-Konstantinović, Zora, Radojčić, Marija B., "Superoxide dismutases and p53 protein levels in blood cells of breast cancer patients" in Journal of Balkan Union of Oncology., 9, no. 3 (2004):283-287,
https://hdl.handle.net/21.15107/rcub_vinar_10582 .

TY  - JOUR
AU  - Nikolić-Vukosavljević, Dragica
AU  - Todorović-Raković, N
AU  - Demajo, Miroslav
AU  - Ivanović, Vesna
AU  - Neskovic, B
AU  - Markicevic, M
AU  - Nešković-Konstantinović, Zora
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2869
AB  - A pilot study was conducted to assess whether plasma levels of transforming growth factor-beta 1 (TGF-beta 1) might facilitate biological subgrouping of postmenopausal metastatic breast cancer patients, and, accordingly, its applicability in clinical oncology. This study included 29 postmenopausal metastatic breast cancer patients. Plasma TGF-beta 1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Estrogen and progesterone receptors were assayed by radioligand binding, in accordance with the recommendation of the EORTC. Concentrations of 17-beta estradiol were determined by using ELISA-microwell method (DIALAB). Overall survival was followed for 24 months for each individual patient. Stratification of the patients by ER/PR status showed that 14 patients with estrogen receptor-negative, progesterone receptor-negative carcinomas displayed a statistically significant increase in plasma TGF-beta 1 levels when compared to plasma TGF-beta 1 levels of 6 patients with ER-positive, PR-positive carcinomas (P=0.04). In this study, 7 out of 14 patients with negative receptors status had no plasma TGF-beta 1 values overlapping with patients having positive receptors status. The TGF-beta 1 cut-off value was defined as the highest plasma TGF-beta 1 level of ER-positive, PR-positive patients: 3.28 ng/ml. This plasma TGF-beta 1 cut-off value defined low-risk subgroup of 19 patients (! 3.28 ng/ml) and high-risk subgroup of 10 patients ( GT 3.28 ng/ml) (P=0.047). Plasma TGF-beta 1-related survival was independent of the classical prognostic factors of metastatic breast cancer. Accordingly, a clinical significance of elevated plasma TGF-beta 1 levels may be suggested.
T2  - Clinical and Experimental Metastasis
T1  - Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients
VL  - 21
IS  - 7
SP  - 581
EP  - 585
UR  - https://hdl.handle.net/21.15107/rcub_vinar_2869
ER  - 

@article{
author = "Nikolić-Vukosavljević, Dragica and Todorović-Raković, N and Demajo, Miroslav and Ivanović, Vesna and Neskovic, B and Markicevic, M and Nešković-Konstantinović, Zora",
year = "2004",
abstract = "A pilot study was conducted to assess whether plasma levels of transforming growth factor-beta 1 (TGF-beta 1) might facilitate biological subgrouping of postmenopausal metastatic breast cancer patients, and, accordingly, its applicability in clinical oncology. This study included 29 postmenopausal metastatic breast cancer patients. Plasma TGF-beta 1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Estrogen and progesterone receptors were assayed by radioligand binding, in accordance with the recommendation of the EORTC. Concentrations of 17-beta estradiol were determined by using ELISA-microwell method (DIALAB). Overall survival was followed for 24 months for each individual patient. Stratification of the patients by ER/PR status showed that 14 patients with estrogen receptor-negative, progesterone receptor-negative carcinomas displayed a statistically significant increase in plasma TGF-beta 1 levels when compared to plasma TGF-beta 1 levels of 6 patients with ER-positive, PR-positive carcinomas (P=0.04). In this study, 7 out of 14 patients with negative receptors status had no plasma TGF-beta 1 values overlapping with patients having positive receptors status. The TGF-beta 1 cut-off value was defined as the highest plasma TGF-beta 1 level of ER-positive, PR-positive patients: 3.28 ng/ml. This plasma TGF-beta 1 cut-off value defined low-risk subgroup of 19 patients (! 3.28 ng/ml) and high-risk subgroup of 10 patients ( GT 3.28 ng/ml) (P=0.047). Plasma TGF-beta 1-related survival was independent of the classical prognostic factors of metastatic breast cancer. Accordingly, a clinical significance of elevated plasma TGF-beta 1 levels may be suggested.",
journal = "Clinical and Experimental Metastasis",
title = "Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients",
volume = "21",
number = "7",
pages = "581-585",
url = "https://hdl.handle.net/21.15107/rcub_vinar_2869"
}

Nikolić-Vukosavljević, D., Todorović-Raković, N., Demajo, M., Ivanović, V., Neskovic, B., Markicevic, M.,& Nešković-Konstantinović, Z.. (2004). Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients. in Clinical and Experimental Metastasis, 21(7), 581-585.
https://hdl.handle.net/21.15107/rcub_vinar_2869

Nikolić-Vukosavljević D, Todorović-Raković N, Demajo M, Ivanović V, Neskovic B, Markicevic M, Nešković-Konstantinović Z. Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients. in Clinical and Experimental Metastasis. 2004;21(7):581-585.
https://hdl.handle.net/21.15107/rcub_vinar_2869 .

Nikolić-Vukosavljević, Dragica, Todorović-Raković, N, Demajo, Miroslav, Ivanović, Vesna, Neskovic, B, Markicevic, M, Nešković-Konstantinović, Zora, "Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients" in Clinical and Experimental Metastasis, 21, no. 7 (2004):581-585,
https://hdl.handle.net/21.15107/rcub_vinar_2869 .

TY  - CONF
AU  - Todorović-Raković, N.
AU  - Ivanović, Vesna
AU  - Demajo, Miroslav
AU  - Nešković-Konstantinović, Zora
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2718
C3  - European Journal of Cancer Supplements / EJC Supplements
T1  - Transforming growth factor-beta1 and steroid receptor status in breast cancer
VL  - 2
IS  - 3
SP  - 105
EP  - 105
DO  - 10.1016/S1359-6349(04)90778-1
ER  - 

@conference{
author = "Todorović-Raković, N. and Ivanović, Vesna and Demajo, Miroslav and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica",
year = "2004",
journal = "European Journal of Cancer Supplements / EJC Supplements",
title = "Transforming growth factor-beta1 and steroid receptor status in breast cancer",
volume = "2",
number = "3",
pages = "105-105",
doi = "10.1016/S1359-6349(04)90778-1"
}

Todorović-Raković, N., Ivanović, V., Demajo, M., Nešković-Konstantinović, Z.,& Nikolić-Vukosavljević, D.. (2004). Transforming growth factor-beta1 and steroid receptor status in breast cancer. in European Journal of Cancer Supplements / EJC Supplements, 2(3), 105-105.
https://doi.org/10.1016/S1359-6349(04)90778-1

Todorović-Raković N, Ivanović V, Demajo M, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. Transforming growth factor-beta1 and steroid receptor status in breast cancer. in European Journal of Cancer Supplements / EJC Supplements. 2004;2(3):105-105.
doi:10.1016/S1359-6349(04)90778-1 .

Todorović-Raković, N., Ivanović, Vesna, Demajo, Miroslav, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, "Transforming growth factor-beta1 and steroid receptor status in breast cancer" in European Journal of Cancer Supplements / EJC Supplements, 2, no. 3 (2004):105-105,
https://doi.org/10.1016/S1359-6349(04)90778-1 . .

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Todorović-Raković, N
AU  - Demajo, Miroslav
AU  - Nešković-Konstantinović, Zora
AU  - Subota, Vesna
AU  - Ivanišević-Milovanović, Olivera
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2003
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2617
AB  - We examined the association between an elevated plasma TGF-beta(1) level and the disease progression of advanced breast cancer (BC) patients (n = 44). TGF-beta(1) levels were detected by an enzyme-linked immunosorbent assay (ELISA). Platelet carryover and in vitro platelet activation in our plasma samples was assessed and found to be insignificant. Plasma TGF-beta(1) values were significantly elevated (P LT 0.05) in stage IIIB/IV patients (median value: 2.40 ng/ml, range: 0.13-8.48 ng/ml, n=44) compared with healthy donors (median value: 1.30 ng/ml, range: 0.41-4.93 ng/ml, n=36). Although pronounced in metastatic patients, especially those who had been newly diagnosed, TGF- and beta;(1) elevation was independent of tumour mass, site of distant metastases, histopathological type, steroid receptor (SR) content and age of the BC patients. Follow-up of 6 patients indicated a relationship between the plasma TGF- and beta;(1) and the patients response. This suggests that TGF- and beta;(1), may be a promising prognostic marker for breast cancer patients with advanced disease. Confirmatory large-scale studies are needed, particularly given the overlap of values between our different subgroups analysed.
T2  - European Journal of Cancer
T1  - Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression
VL  - 39
IS  - 4
SP  - 454
EP  - 461
DO  - 10.1016/S0959-8049(02)00502-6
ER  - 

@article{
author = "Ivanović, Vesna and Todorović-Raković, N and Demajo, Miroslav and Nešković-Konstantinović, Zora and Subota, Vesna and Ivanišević-Milovanović, Olivera and Nikolić-Vukosavljević, Dragica",
year = "2003",
abstract = "We examined the association between an elevated plasma TGF-beta(1) level and the disease progression of advanced breast cancer (BC) patients (n = 44). TGF-beta(1) levels were detected by an enzyme-linked immunosorbent assay (ELISA). Platelet carryover and in vitro platelet activation in our plasma samples was assessed and found to be insignificant. Plasma TGF-beta(1) values were significantly elevated (P LT 0.05) in stage IIIB/IV patients (median value: 2.40 ng/ml, range: 0.13-8.48 ng/ml, n=44) compared with healthy donors (median value: 1.30 ng/ml, range: 0.41-4.93 ng/ml, n=36). Although pronounced in metastatic patients, especially those who had been newly diagnosed, TGF- and beta;(1) elevation was independent of tumour mass, site of distant metastases, histopathological type, steroid receptor (SR) content and age of the BC patients. Follow-up of 6 patients indicated a relationship between the plasma TGF- and beta;(1) and the patients response. This suggests that TGF- and beta;(1), may be a promising prognostic marker for breast cancer patients with advanced disease. Confirmatory large-scale studies are needed, particularly given the overlap of values between our different subgroups analysed.",
journal = "European Journal of Cancer",
title = "Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression",
volume = "39",
number = "4",
pages = "454-461",
doi = "10.1016/S0959-8049(02)00502-6"
}

Ivanović, V., Todorović-Raković, N., Demajo, M., Nešković-Konstantinović, Z., Subota, V., Ivanišević-Milovanović, O.,& Nikolić-Vukosavljević, D.. (2003). Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression. in European Journal of Cancer, 39(4), 454-461.
https://doi.org/10.1016/S0959-8049(02)00502-6

Ivanović V, Todorović-Raković N, Demajo M, Nešković-Konstantinović Z, Subota V, Ivanišević-Milovanović O, Nikolić-Vukosavljević D. Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression. in European Journal of Cancer. 2003;39(4):454-461.
doi:10.1016/S0959-8049(02)00502-6 .

Ivanović, Vesna, Todorović-Raković, N, Demajo, Miroslav, Nešković-Konstantinović, Zora, Subota, Vesna, Ivanišević-Milovanović, Olivera, Nikolić-Vukosavljević, Dragica, "Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression" in European Journal of Cancer, 39, no. 4 (2003):454-461,
https://doi.org/10.1016/S0959-8049(02)00502-6 . .

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Todorović-Raković, N
AU  - Demajo, Miroslav
AU  - Nešković-Konstantinović, Zora
AU  - Nikolić-Vukosavljević, Dragica
AU  - Ivanišević-Milovanović, Olivera
AU  - Mitrovic, L
PY  - 2001
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2438
AB  - There has been much controversy concerning the detection of plasma TGF-beta (1) levels in breast cancer patients. The present study provides preliminary evidence on underestimated plasma TGF-beta (1) levels due to ex vivo proteolysis and previous therapeutic treatment of breast cancer patients, as detected by a commercial ELISA immunoassay. Our results revealed that the addition of protease inhibitors: phenylmethylsulfonyl fluoride and aprotinin, to the plasma preparation of healthy volunteers, has increased TGF-beta (1) median Value from 3.1 ng/mL to 33.9 ng/mL. Relative to that, in protease-inhibited plasma of locally advanced/metastatic breast cancer patients, significantly elevated TGF-beta (1) was observed (median value: 65.5 ng/mL), which included untreated and previously treated patients with median values of: 74.2 ng/mL and 58.1 ng/mL, respectively. These findings indicate to the potential usefulness of this plasma marker in breast cancer prognosis, thus deserving future clinical attention.
T2  - Jugoslovenska Medicinska Biohemija
T1  - Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients
VL  - 20
IS  - 2
SP  - 81
EP  - 87
UR  - https://hdl.handle.net/21.15107/rcub_vinar_2438
ER  - 

@article{
author = "Ivanović, Vesna and Todorović-Raković, N and Demajo, Miroslav and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica and Ivanišević-Milovanović, Olivera and Mitrovic, L",
year = "2001",
abstract = "There has been much controversy concerning the detection of plasma TGF-beta (1) levels in breast cancer patients. The present study provides preliminary evidence on underestimated plasma TGF-beta (1) levels due to ex vivo proteolysis and previous therapeutic treatment of breast cancer patients, as detected by a commercial ELISA immunoassay. Our results revealed that the addition of protease inhibitors: phenylmethylsulfonyl fluoride and aprotinin, to the plasma preparation of healthy volunteers, has increased TGF-beta (1) median Value from 3.1 ng/mL to 33.9 ng/mL. Relative to that, in protease-inhibited plasma of locally advanced/metastatic breast cancer patients, significantly elevated TGF-beta (1) was observed (median value: 65.5 ng/mL), which included untreated and previously treated patients with median values of: 74.2 ng/mL and 58.1 ng/mL, respectively. These findings indicate to the potential usefulness of this plasma marker in breast cancer prognosis, thus deserving future clinical attention.",
journal = "Jugoslovenska Medicinska Biohemija",
title = "Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients",
volume = "20",
number = "2",
pages = "81-87",
url = "https://hdl.handle.net/21.15107/rcub_vinar_2438"
}

Ivanović, V., Todorović-Raković, N., Demajo, M., Nešković-Konstantinović, Z., Nikolić-Vukosavljević, D., Ivanišević-Milovanović, O.,& Mitrovic, L.. (2001). Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients. in Jugoslovenska Medicinska Biohemija, 20(2), 81-87.
https://hdl.handle.net/21.15107/rcub_vinar_2438

Ivanović V, Todorović-Raković N, Demajo M, Nešković-Konstantinović Z, Nikolić-Vukosavljević D, Ivanišević-Milovanović O, Mitrovic L. Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients. in Jugoslovenska Medicinska Biohemija. 2001;20(2):81-87.
https://hdl.handle.net/21.15107/rcub_vinar_2438 .

Ivanović, Vesna, Todorović-Raković, N, Demajo, Miroslav, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, Ivanišević-Milovanović, Olivera, Mitrovic, L, "Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients" in Jugoslovenska Medicinska Biohemija, 20, no. 2 (2001):81-87,
https://hdl.handle.net/21.15107/rcub_vinar_2438 .